Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus FLOVENT DISKUS 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus FLOVENT DISKUS 50.
FLOVENT DISKUS 250 vs FLOVENT DISKUS 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, reduction of eosinophil recruitment, and suppression of airway hyperresponsiveness.
Glucocorticoid receptor agonist; anti-inflammatory transcription factor modulation; inhibits phospholipase A2, reduces arachidonic acid release, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and inflammatory cell migration.
250 mcg inhaled orally via DISKUS twice daily (500 mcg total daily dose).
1 inhalation (50 mcg) twice daily, administered via oral inhalation.
None Documented
None Documented
Approximately 10-12 hours (terminal elimination half-life in asthmatics).
Terminal elimination half-life is approximately 14-17.5 hours; this supports once- or twice-daily dosing in asthma maintenance.
Renal (approximately 5% as unchanged drug); fecal (majority as metabolites and unabsorbed drug).
Primarily fecal (87-90%) after hepatic metabolism; renal excretion accounts for <5% as unchanged drug and metabolites.
Category C
Category C
Corticosteroid
Corticosteroid